Page 12 - Eric Soyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer Management to host Conference...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 ... Erytech Pharma S.A.April 28, 2021 GMT ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details Publication of Q1 2021 results on 4 May 2021 after market close Lyon (France) and Cambridge, MA (U.S.), April 29, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red b...

29.04.2021 - ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 conference call Publication of Q1 2021 results on 4 May 2021 after market close Lyon (France) and Cambridge, MA (U.S.), April 29, 2021 – ERYTECH Pharma ... Seite 1

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL Erytech Pharma S.A.April 20, 2021 GMT ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL ERYTECH invited by FDA to request a pre-BLA meeting First step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the NOPHO-sponsored Phase 2 clinical trial Lyon (France) and Cambridge, MA (U.S.), April 2...

. The rESPECT IST (NCT04292743) is a single arm, dose escalating Phase 1 clinical trial to evaluate the safety of eryaspase in combination with modified FOLFIRINOX. The trial is conducted by Dr Marcus Noel, Associate Professor of Medicine at Georgetown University, Washington DC, USA, and will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer. FOLFIRINOX is one of the most commonly utilized first-line chemotherapy regimens for the treatment of pancreatic cancer, despite its toxicity. The trial was laun...